Tumor size—inconsistently defined biomarker often used for determining efficacy of cancer therapeutics
Type 2 diabetes—diabetes mellitus of a common form that develops especially in adults and most often in obese individuals and that is characterized by hyperglycemia resulting from impaired insulin utilization coupled with the body’s inability to compensate with increased insulin production
Utilization—contextual analysis based on the specific use proposed and the applicability of available evidence to this use. This includes a determination of whether the validation and qualification conducted provide sufficient support for the use proposed
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary . Washington, DC: The National Academies Press,
Please select a format: